Cargando…

Bruton’s tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia

Detalles Bibliográficos
Autores principales:	Nimmagadda, S C, Frey, S, Edelmann, B, Hellmich, C, Zaitseva, L, König, G M, Kostenis, E, Bowles, K M, Fischer, T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843904/ https://www.ncbi.nlm.nih.gov/pubmed/29109446 http://dx.doi.org/10.1038/leu.2017.324

Ejemplares similares

ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia
por: Germano, Giuseppe, et al.
Publicado: (2017)

MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
por: Winters, Amanda C., et al.
Publicado: (2017)

RNA binding proteins in MLL-rearranged leukemia
por: Tran, Tiffany M., et al.
Publicado: (2022)

KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements
por: Au, Yan Zi, et al.
Publicado: (2021)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
por: Montoya, Skye, et al.
Publicado: (2023)

Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia
por: Zhao, Lianzhong, et al.
Publicado: (2021)

S116: CELLULAR AND MOLECULAR MECHANISMS OF EVI1-EXPRESSING MLL-REARRANGED ACUTE MYELOID LEUKEMIA
por: Châtel-Soulet, Hugues-Etienne, et al.
Publicado: (2022)

FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
por: Zhu, Xiao-Na, et al.
Publicado: (2023)

PB1803: SMAD1 IS A TUMOR SUPPRESSOR IN ACUTE MYELOID LEUKEMIA WITH MLL REARRANGEMENT
por: Dietsche, Lisa, et al.
Publicado: (2023)

Identification of Genes Transcriptionally Responsive to the Loss of MLL Fusions in MLL-Rearranged Acute Lymphoblastic Leukemia
por: van der Linden, Marieke H., et al.
Publicado: (2015)

The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
por: Gordon, Max J., et al.
Publicado: (2021)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures
por: Zangrando, Andrea, et al.
Publicado: (2009)

Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance
por: Uckun, Fatih M., et al.
Publicado: (2022)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment
por: Good, Logan, et al.
Publicado: (2021)

Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
por: Feng, Zizhen, et al.
Publicado: (2016)

Uncovering NOTCH1 as a Promising Target in the Treatment of MLL-Rearranged Leukemia
por: Fischer, Jacqueline, et al.
Publicado: (2023)

An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in MLL1-rearranged acute myeloid leukemia in mice
por: Wang, Hao, et al.
Publicado: (2020)

Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD)
por: Sun, Q-Y, et al.
Publicado: (2017)

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
por: Arneson, Laura C, et al.
Publicado: (2021)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: Smith, C. I. Edvard, et al.
Publicado: (2021)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
por: Wang, Xianhui, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia
por: Verboon, Lonneke J., et al.
Publicado: (2016)

Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
por: Ye, Jing, et al.
Publicado: (2019)

The landscape of somatic mutations in Infant MLL rearranged acute lymphoblastic leukemias
por: Andersson, Anna K, et al.
Publicado: (2015)

Replication stress in MLL-rearrangements
por: Milyavsky, Michael, et al.
Publicado: (2015)

High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia
por: Wander, Priscilla, et al.
Publicado: (2021)

The developmental stage of the hematopoietic niche regulates lineage in MLL-rearranged leukemia
por: Rowe, R. Grant, et al.
Publicado: (2019)

Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia
por: Hurtz, Christian, et al.
Publicado: (2019)

Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia
por: Brzezinka, Krzysztof, et al.
Publicado: (2019)

The Use of Bruton’s Tyrosine Kinase Inhibitors to Treat Allergic Disorders
por: Dispenza, Melanie C.
Publicado: (2021)

Bruton's Tyrosine Kinase Regulates the Activation of Gene Rearrangements at the λ Light Chain Locus in Precursor B Cells in the Mouse
por: Dingjan, Gemma M., et al.
Publicado: (2001)

Structural mechanism for Bruton’s tyrosine kinase activation at the cell membrane
por: Wang, Qi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ssj8gnmiooinlaco75uopl85d9